NiCox Closes Out €100M Fund with €70M Discounted Rights
BioWorld Today Correspondent
NiCox SA completed the second leg of a two-part €100 million (US$143.2 million) fundraising by raising €69.9 million in a discounted rights offering, a financing that the firm believes will be the last it needs.
One reason why came shortly afterward when NiCox filed for approval of naproxcinod in osteoarthritis with the European Medicines Agency.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter